Who he is
Role check (2026-10-03): Co-founder & CEO, Colossal Biosciences (Dallas, founded Sep 2021 with Harvard geneticist George Church) — unchanged, confirmed on stage at Moonshots LIVE 2026-09-25 and in TIME, 2026-08-24. New hats since the file was built: co-founder of Astromech (Colossal AI spinout, founded with Church Sep 2025, $3.8B valuation on $60M raised, 2026-08-21, pre-revenue); member of the White House-requested UAP Science Advisory Council chaired by Avi Loeb (DefenseScoop, 2026-06-17). Founder of the Colossal Foundation (501(c)(3), Oct 2024; ~$100M raised by Dec 2025 per Wikipedia — not separately sourced). Prior exits: Simply Interactive (2010), Chaotic Moon → Accenture (2015), Team Chaos → Zynga (2016), Conversable → LivePerson (2018), Hypergiant → Trive Capital (2023). Born 1981, Austin; Baylor.
Company state (as of 2026-10-03): $555M raised (Series C total $320M: $200M Jan 2025 led by TWG Global + $120M Sep 2025 from USIT, Bob Nelsen, Peter Jackson) at a $10.32B mark (GenomeWeb, Sep 2025). In talks to raise at $25–26B led by TWG Global (Axios Pro, 2026-09-30, headline only — paywalled; TechCrunch reported the $20–30B range on 2026-07-20). Six announced species programs: mammoth, thylacine, dodo, dire wolf, moa (Jul 2025, with Peter Jackson and Ngāi Tahu), bluebuck (Apr 2026). Spinouts: Form Bio (2022, $30–35M; only disclosed customer is Colossal), Breaking (2024, $10.5M seed, plastic-eating microbe), Astromech (2025). First acquisition: Viagen Pets & Equine (Nov 2025) — the pet/horse cloning company, now a wholly owned subsidiary and Colossal's first real revenue line. Colossal Australia (Aug 2025, acquired the TIGRR lab). UAE invested $60M and bought a cryo-biovault deal (Dubai, Feb 2026). TechCrunch: "Colossal has started generating revenue over the last year."
One-line position: Extinction is an engineering problem, and the tools built to reverse it are worth more than the reversals — de-extinction is the flagship that funds and markets a conservation-biotech platform. Unchanged, and the past year's behavior (Viagen, Astromech, biovaults, government contracts) says he means the second half more than the first.
Discipline & technical bet
Not a scientist — a serial software founder running a genomics company, with the scientific credibility supplied by George Church, CSO Beth Shapiro and a large staffed research team. That division is the whole structure: Lamm raises, narrates and merchandises; the lab does the biology. The concrete wager is “functional de-extinction” — identify the core genes that produce a species' defining traits and engineer them into the closest living relative, rather than resurrect an exact genome. Commercially the bet is that the tool-chain spins out: the editing, cloning, artificial-womb and biobanking technologies developed to make a mammoth have conservation and biomedical value regardless of whether the mammoth arrives.
2026 update to the bet: the technical frontier he now sells is multiplex editing (hundreds of edits at once — “300 simultaneous gene edits at 90%+ efficiency”, testing 1,000) and ex-utero gestation (growing a mammal entirely outside a womb): “I think within 24 months, Colossal will birth animal mammals fully ex utero” (Moonshots LIVE, 2026-09-25, via Scuttlebutt, 2026-10-01). The mammoth itself has quietly moved from a date to a decade.
Key claims (Says)
- Definitional (and contested): functional de-extinction — a proxy carrying the defining traits counts as the species restored. He cites an IUCN framework in support. This definition is doing enormous work and most of the controversy lives inside it. 2026-10-03: the IUCN's own canid body rejected the application — see Delta log.
- On the dire wolves: the animals possess “nearly all defining characteristics” warranting separate-species classification, backed by a submitted peer-reviewed study arguing dire wolves are a distinct evolutionary lineage. The study is now published (Cell Genomics, 2026-07-27) — but it is about 13,000- and 72,000-year-old fossils, not the three living animals.
- On critics: the objection that these are genetically modified grey wolves is “a stupid argument” — his own words, April 2025 (Fast Company, 2025-04-12). Notable for the register, not just the content. His own CSO disagrees in public: “Our animals are grey wolves with 20 edits that are cloned” (Beth Shapiro to New Scientist, May 2025, via Live Science).
- Normative: de-extinction is conservation, not spectacle — the technology stack transfers directly to saving species that are still alive. Backed in 2025–26 by red-wolf clones, a biovault programme and the Viagen purchase; contested by the IUCN CSG (“does not contribute to conservation”) and by red-wolf scientists who say the clones are from coyote-heavy “ghost wolves” that are “federally… not” red wolves (MIT Technology Review, 2026-04-20).
- Commercial: the flagship species exist to “excite children” and carry the biodiversity message. He is unusually candid that the mammoth is a marketing instrument as well as a scientific goal.
- Empirical: the platform generates spinout value independent of the headline projects. Now partly demonstrated — Astromech priced at $3.8B by outside investors, Viagen revenue, a UAE contract — though no spinout has yet disclosed an outside paying customer (Form Bio: Colossal only; Astromech: pre-revenue).
- New (2026): “The core of Colossal is a trillion-dollar opportunity” (Dallas Innovates, 2025-01-15); designer animals with specified traits within <10 years; half of global biodiversity gone within 25 years (Moonshots LIVE, 2026-09-25). The first is a valuation claim in the grammar of a mission.
Notable predictions — with falsifiable checks
- Woolly mammoth calf by 2028. Wrong — retired by Lamm himself. Original plan: embryos 2026, pregnancy 2027, late-2028 birth. TIME, 2026-08-24: “We are thinking it will be in the early 2030s. We don't have a hard date. Not 2036, but not 2030 either.” Reason given: the edit count rose from ~60 to ~150 genes “and potentially rising.” New check: a confirmed elephant (or ex-utero) pregnancy carrying mammoth edits announced by 2029-12-31; a living calf by 2033-12-31. Rich's criterion, decided now: a calf counts only if Colossal publishes the edit list and an independent lab confirms the edits; a “woolly elephant” with <50 verified mammoth-derived edits is a hairy elephant, not a mammoth.
- (April 2025) “We de-extincted the dire wolf.” Wrong on the strict reading, now on the record of the company's own CSO and the IUCN. What was demonstrably done: grey wolf DNA edited at 14 genes for 20 traits, embryos cloned, gestated in domestic dog surrogates; males born 2024-10-01, female 2025-01-30. IUCN SSC Canid Specialist Group, 2025-04-18: “The three animals produced by Colossal are not dire wolves. Nor are they proxies of the dire wolf based on IUCN SSC guiding principles” (statement PDF). Both statements remain true simultaneously — the edits are real, the species claim is not — which is exactly why the framing matters. Forward check: does Colossal publish a phenotype paper on the three living animals (skull, size, behavior vs. grey wolf) by 2027-12-31? The IUCN's first objection was “no evidence that the genetically modified animals are phenotypically distinct from the grey wolf.”
- Thylacine and dodo. Still no public dated commitment (Held as written, but unfalsifiable — rewritten). Progress claimed: thylacine genome 99.9% (Oct 2024), 300 edits in one dunnart cell line; dodo — first culture of pigeon primordial germ cells, Nicobar pigeon colony in Texas, Mauritius Dodo Advisory Committee (Sep 2025). New check: a hatched dodo-proxy chick or a born thylacine-proxy joey announced by 2030-12-31; failing that, a published date by 2027-12-31.
- Spinout value by 2028. Held, early and partial. Outside capital priced Astromech at $2B (Mar 2026) then $3.8B (Aug 2026); Viagen brings real customers (pets, horses, livestock); UAE $60M + biovault deal; TechCrunch: revenue has begun. Still missing: any spinout with a disclosed outside paying customer. Check (unchanged): independent revenue or a spinout with named outside customers by 2028-12-31 — Viagen counts only as acquired revenue, not platform revenue.
- The $10.2B valuation on $437M raised. Drifted — mark exceeded, warning branch triggered. The round in talks is $25–26B, a 2.5x step-up (Axios, 2026-09-30; TechCrunch, 2026-07-20). But it is led by TWG Global — Mark Walter's existing-investor vehicle, a generalist — not a life-sciences fund. The file said: who prices the round tells you what is being bought. An insider marking up his own position is the weakest kind of price signal. Check: does the round close by 2027-03-31, who else is in it, and does any biotech specialist lead a later round?
- New: “within 24 months, Colossal will birth animal mammals fully ex utero” (2026-09-25). Check: a peer-reviewed or independently verified live mammalian birth with no surrogate by 2028-09-30. Prior claim in the same family: a 17-person artificial-womb team has cultured marsupial embryos “over halfway through pregnancy.”
- New: “Not 2036, but not 2030 either” is itself a (number, horizon) pair — log every restatement; a second slip past 2033 grades the programme, not the date.
Revealed behavior (Does)
- Announces first and publishes second (as of 2025-04 → 2026-07). The dire wolves were unveiled to media 2025-04-07 with the supporting study submitted 2025-04-10; it was accepted 2026-06-25 and published 2026-07-27 — 15 months after the press cycle, and on fossil ancestry, not on the living animals. That ordering is the central behavioral fact — a product-launch sequence applied to a scientific claim.
- Buys revenue rather than waiting for it (2025-11). Viagen — a 23-year-old pet-cloning business with 15 species cloned — is Colossal's first acquisition and first real revenue. The platform thesis was validated by purchase, not by spinout.
- Prices his own spinout aggressively (2025-09 → 2026-08). Astromech went $2B → $3.8B in five months while pre-revenue and “in deep research and validation mode.” Lamm is CEO of the parent and co-founder of the child.
- Moved the mammoth date by half a decade without a press release (2026-08). The slip surfaced in a TIME interview, not a Colossal announcement. Compare the cadence of the firsts.
- Sells to sovereigns (2026-02). UAE biovault in Dubai and $60M invested; conservation tech “offered to the U.S. government.” Government and sovereign-wealth money is the revenue line that does not require a mammoth.
- Recruited credibility rather than claiming it. Co-founding with George Church, then hiring Beth Shapiro as CSO — and Shapiro's public “grey wolves with 20 edits” is the price of that credibility: it is now on the record against his own framing.
- Chose charismatic species deliberately — mammoth, dire wolf, dodo, thylacine, moa (with Peter Jackson), bluebuck. Every one is a story before it is a genome. He says so openly.
- Named them Romulus, Remus and Khaleesi. Two founding myths and a Game of Thrones reference. George R.R. Martin is a Colossal investor and cultural adviser.
- Fights critics publicly and dismissively — and in 2025 the fight escalated: a cease-and-desist letter to evolutionary biologist Vincent Lynch for “increasingly hostile and now defamatory attacks”; four academic critics (Lynch, Herridge, Dibble, Rawlence) reported AI-generated hit pieces and bogus copyright strikes (New Scientist, 2025-07; EMBO Reports “Scientists targeted by dark PR tactics,” 2025). Colossal: “neither Colossal, nor any of its investors, are involved in commissioning negative stories about critics.” Attribution of the smear campaign is unproven; the cease-and-desist is on the record.
- Collects adjacent seats (2026-06). UAP Science Advisory Council — outside his field, inside the White House orbit. A founder diversifying his access, not his science.
Feels
Evident delight in the audacity of the thing — the sound of a howl, the spectacle, the children. It reads as real rather than manufactured, and it is his most persuasive quality. Underneath, a founder's impatience with gatekeeping that shades into contempt when the gatekeepers are scientists: the “stupid argument” response is the tell, and the cease-and-desist letter is the same feeling with a lawyer attached. He appears to experience taxonomic objections as pedantry obstructing wonder, which is exactly how a marketer would experience them and not how a scientist would.
Hears
An extraordinarily favourable feed — Rogan, Armchair Expert (Sep 2026), Moonshots, TIME100 Next (2025), a Gizmodo Science Fair prize (2026-09-29). The scientific criticism reaches him filtered through media framing rather than through peer review, because the announcements precede the papers — by the time specialists respond, the story has already been told. He has constructed an information environment where the applause arrives first and the correction arrives late and quieter. The one voice he cannot filter is his own CSO.
Sees
Sees extinction as a solvable engineering problem, which is a genuinely generative reframe and the reason serious scientists work there. Also sees, clearly and unsentimentally, that biodiversity loss has a public-attention problem that a mammoth solves and a spreadsheet does not. The blind spot is ecological rather than genetic: producing an organism with a species' traits is not restoring the species' role — habitat, population, behaviour and range are the hard parts, and they are not gene-editing problems. The IUCN CSG made exactly this argument on 2025-04-18: the dire wolf's “ecological context… is no longer present.”
Incentive map
Very heavy discount, and the structure is unusual. Colossal's valuation rests on narrative more than on revenue — the revenue that now exists (Viagen pet cloning, a UAE biovault, government contracts) is a rounding error against a $25B ask. Every announcement is a fundraising event, and the pending round makes Q4 2026 an announcement-dense quarter by construction. The permissive “functional de-extinction” definition is not incidental: it is the definition under which milestones can be declared, and declared milestones are what support the mark.
New conflicts (2026-10-03): (1) Astromech — Lamm co-founded and holds equity in a spinout his parent company incubated; the spinout's $3.8B mark is a reason to keep the parent's story hot. (2) TWG Global leading the new round is an existing investor marking up its own 2025 position — the price is an insider's price. (3) Sovereign customers (UAE) and a White House advisory seat (UAP council) give him access-dependence on governments he will not criticise. (4) George R.R. Martin is both investor and the reason the dire wolf had an audience.
Cannot say: that the dire wolves are edited grey wolves (his CSO said it for him); that the mammoth timeline may slip (it did, in an interview); that de-extinction may never be ecologically meaningful; that the conservation framing arrived partly to answer critics; that the spinouts have no outside customers yet. Grade him on the ex-utero birth (Sep 2028), the mammoth pregnancy (2029), and whether any spinout ever sells to a stranger — not on unveilings.
Theories aligned with
- Conservation biotech — genetic rescue of living endangered species (the strongest and least contested part of the case; the red-wolf clones are its first real test, and even that is disputed)
- Functional de-extinction — proxy species over exact genomes (rejected for the dire wolf by the body whose principles he cites)
- Moonshot-as-marketing — a charismatic impossible goal as the engine of funding and attention
- Techno-solutionism, biodiversity variant — extinction as an engineering failure rather than a systems one
- Platform-from-flagship — the 2026 behavior (Viagen, Astromech, biovaults) says this is the operative theory now
- Adjacent to Rich's Leapfrog for Good framing — bypassing slow conservation institutions with capital and technology
What he's reacting against
- Conservation's failure to hold public attention — his most defensible grievance, and largely correct
- Academic caution as an obstacle to ambition
- Grant-cycle science — slow, incremental, structurally unable to attempt something like this
- Taxonomic gatekeeping — he treats species-definition arguments as obstruction rather than as the substance
- Doomer environmentalism — he sells restoration where the field sells loss, which is genuinely differentiated positioning
- Named critics — Lynch, Herridge, Dibble, Rawlence, Hinton; by 2025 the reaction had a legal department
Where he overlaps / splits (with Rich)
- Overlaps directly with Rich's Leapfrog for Good framing (a working thesis, not one of the 19 numbered principles) — and is the softer version of the same test Luckey poses. Colossal bypasses the conservation apparatus with capital and technology and delivers a visible outcome. He is what leapfrogging looks like when the outcome is real but the claim about it is inflated — a failure mode the framing hasn't yet named.
- Splits hard on §10 Research Like a Scientist, Build Like an Artisan — and this is the important one. Announce-then-publish is the inverse of research like a scientist. Your whole persona apparatus grades people on falsifiability and calibrated language; Colossal's central claim rests on a definition chosen by the claimant — and the one body whose definition he borrowed has said it does not apply. If you keep one line from this file, keep that.
- Overlaps on §07 Iconoclast and §19 Dream & Ask What-If — he asked “what if extinction were reversible?” and built a $10B company on the question. The split is that §10 is supposed to govern what you do after the what-if.
- Overlaps on the XPRIZE Lens — would someone fund this because it matters? Colossal is the purest existing example of impact-framing successfully attracting non-impact capital (celebrities, a Dodgers owner, a sovereign fund).
- Splits on §12 Embrace the Tensions. The genuine tension here — spectacle funds the science and spectacle corrupts the claims — is one he refuses to hold. He resolves it by calling the critics stupid, then by sending them letters. You would hold it; that difference is the whole read on him.
- Connects to Caring. Biodiversity sits in your Caring domain alongside public lands. The useful question is whether de-extinction moves conservation outcomes or diverts attention and money from habitat — the IUCN CSG's formal position is the latter, and that question is genuinely open, not rhetorical.
- Overlaps with Diamandis on moonshot-as-attention-machine; both understand that an impossible goal is a funding instrument. They now share a stage (Moonshots LIVE) — the bench-independence caveat from the 2026-09-04 batch applies.
- Splits with Mollick and Mitchell in temperament — they are the empiricist counterweight your bench uses, and they would not let the dire wolf framing pass.
Track record
Verified this pass: Colossal founded Sep 2021 with George Church; $555M raised ($15M seed 2021 · $60M A 2022 · $150M B 2023 · $320M C 2025) at $10.32B; three edited canines born 2024-10-01 and 2025-01-30; dire-wolf ancestry paper published Cell Genomics 2026-07-27 (Gedman … Church, Lamm, Shapiro); woolly mice (Mar 2025); elephant iPSCs (Mar 2024); pigeon primordial germ cells (Sep 2025); red-wolf clones (Apr 2025 one; Sep 2025 four more); Viagen acquired (2025-11-04); Astromech $3.8B (2026-08-21); Gizmodo Science Fair winner (2026-09-29). Prior to Colossal, five software/AI companies founded and sold.
The honest read: as a founder, the record is real and growing — he raised more than half a billion dollars for a genuinely hard scientific programme, assembled serious people to run it, and in 2025–26 bolted a revenue business and a second unicorn onto it. As a de-extinction record, nothing has yet been established on the strict reading of the claim, his CSO has said so, and the first dated promise (mammoth 2028) has slipped to the 2030s. Those are different scoreboards and his coverage consistently merges them. The ex-utero birth (Sep 2028) is now the nearest date where they separate.
Empirical vs normative
Empirical (verifiable): the edits made, the animals produced, the surrogate species, the funding and valuation, the acquisitions. Definitional (presented as empirical — the crux): that the result is a dire wolf. This is not a finding, it is a category judgment made by the party who benefits from it, delivered in the grammar of a result — and the IUCN CSG, whose principles he invoked, delivered the opposite judgment eleven days later. Normative: that de-extinction is a worthwhile use of capital and attention.
The pattern to name: the strongest claim in the corpus is a definition, and it is announced as though it were data. That is the same rhetorical move Salim Ismail makes with the Organizational Singularity, in a different field. The 2026 variant: “a trillion-dollar opportunity” — a valuation claim in the grammar of a mission.
Weak spots / open questions
- The definition is the product. “Functional de-extinction” is chosen by the claimant and makes the claim true by construction. Graded 2026-10-03: Held, and now with the IUCN's rejection on the record.
- Announce-then-publish. Reverses the epistemic order and ensures the correction never catches the claim. Held: 15 months from press day to paper, and the paper is about fossils.
- Ecology, not genetics, is the hard part. An organism with mammoth traits is not a restored mammoth ecology. Held; the IUCN CSG said it first.
- Valuation rests on announcements, not revenue, approvals or customers. Drifted: there is revenue now (Viagen, UAE, government), but it is bought and small against a $25B ask; the lead investor is an insider.
- The conservation framing may be retrofitted. Open: the Colossal Foundation (Oct 2024) and red-wolf work (Apr 2025) post-date the first criticism wave; 2021–22 launch materials still unchecked.
- New — critic handling. A cease-and-desist to a tenured biologist and an unattributed smear campaign against four named critics. Open question: who commissioned the hit pieces? Colossal denies; nobody has shown otherwise. Forward check: any further legal threat to a critic, or any attribution of the 2025 campaign.
- New — the CSO gap. Shapiro says grey wolves; Lamm says dire wolves. Watch whether she stays — her departure would be a signal; her staying while he keeps the framing is a different one.
- New — spinout customers. Three spinouts, ~$100M of outside capital, zero disclosed outside paying customers. Resolve by 2028.
- Question worth asking him directly: what result, on the mammoth, would he accept as a failure — and who decides? Sharper now: he moved the date without saying what moved it except the edit count.
Rich's take
- (your synthesis here)
Delta log
2026-10-03 — validated, rebuilt on v2.5 CSS (5 Held / 3 Drifted / 3 Wrong)
Role check: still Co-founder & CEO, Colossal (Moonshots LIVE 2026-09-25; TIME 2026-08-24). Two hats added: Astromech co-founder (Sep 2025) and UAP Science Advisory Council (Jun 2026). Meta tags: the 2026-09-05 build carried Peter Diamandis's discipline, connects-to and wake_triggers (Giga-XPRIZE, Fountain Life, longevity) — replaced with Lamm's own. § citations: v1 cited §24 (does not exist) and §11/§14 by restatement numbers; corrected to §10 Research Like a Scientist and §12 Embrace the Tensions against _LIFE-PRINCIPLES.html; Leapfrog for Good and the XPRIZE Lens are Rich framings, not numbered principles, and are cited as such.
- Key claim — functional de-extinction, “cites an IUCN framework in support”: Wrong. The IUCN SSC Canid Specialist Group, 2025-04-18: the animals “are not dire wolves. Nor are they proxies of the dire wolf based on IUCN SSC guiding principles” and the work “does not contribute to conservation” (statement). This was public five months before the file was built and the file missed it.
- Key claim — dire wolves have “nearly all defining characteristics,” backed by a submitted study: Drifted. The study published (Cell Genomics, 2026-07-27; received 2025-04-10, accepted 2026-06-25) — but it reconstructs ancient-dire-wolf ancestry (~61% sister to wolves/coyotes/dholes, ~39% South-American-canid lineage, divergence ~4.5 Mya) and says nothing about the three living animals' phenotype. The claim it was cited to support remains unsupported.
- Key claim — “a stupid argument”: Held. Quote verified (Fast Company 2025-04-12); register continued into a cease-and-desist letter to Vincent Lynch (2025-10-06 round-up; New Scientist 2025-07).
- Key claim — de-extinction is conservation: Drifted. Revealed behavior added real conservation tools (red-wolf clones Apr/Sep 2025, Dubai biovault 2026-02-04, Viagen); but the IUCN CSG rejects the conservation contribution and red-wolf geneticists dispute the clones' species identity (MIT TR, 2026-04-20). Stance held, evidence contested.
- Key claim — flagships exist to excite children: Held (restated Moonshots LIVE 2026-09-25).
- Key claim — platform generates spinout value: Held, on direction: Astromech $3.8B (2026-08-21), Viagen (2025-11), revenue begun (TechCrunch 2026-07-20). Caveat logged: no disclosed outside customer at any spinout.
- Prediction — mammoth calf by 2028: Wrong. Lamm, TIME 2026-08-24: “early 2030s… Not 2036, but not 2030 either.” Edit estimate 60 → ~150. v1's “single best test of the entire company” slipped before it could be scored; the v1 open action (confirm 2028 from a primary) is closed — the primary is the retraction.
- Prediction — “We de-extincted the dire wolf”: Wrong on the strict reading, by the company's own CSO (“grey wolves with 20 edits,” May 2025) and the IUCN CSG. v1 graded it “contested”; the contest has a result.
- Prediction — thylacine/dodo dates: Held as written (still no date) but unfalsifiable — rewritten with a 2030 observable.
- Prediction — spinout value by 2028: Held (early, partial — see above).
- Prediction — next round holds $10.2B, led by a life-sciences investor: Drifted. Mark 2.5x higher ($25–26B in talks, Axios Pro 2026-09-30 headline; TechCrunch 2026-07-20) — but led by TWG Global, the generalist existing investor. The file's own warning branch fired.
- Numbers corrected: $437M → $555M total raised (the Sep 2025 $120M extension was already a month old when the file was built); $10.2B → $10.32B; dire-wolf edits specified (14 genes / 20 edits); birth dates added.
- New since 2026-09-05: Astromech $3.8B (08-21); mammoth slip (08-24); Moonshots LIVE ex-utero-in-24-months claim (09-25); Gizmodo Science Fair prize (09-29); TWG round (09-30). Before the build but missed by it: IUCN CSG statement (2025-04-18), Shapiro clarification (2025-05), New Scientist smear-campaign report (2025-07), Cell Genomics paper (2026-07-27), Astromech launch (2025-08/09), Viagen (2025-11), biovault (2026-02), bluebuck (2026-04), red-wolf dispute (2026-04), UAP council (2026-06).
- Tier: quarterly — a monthly-announcing company with a live fundraise and a founder who moves dates in interviews; the framing changes faster than the biology. Confidence raised to medium-high: financials, method, timelines and the critics' record are now all primary-sourced; the spinout-customer question is the main gap.
- Not verified this pass: Axios Pro text (paywalled — valuation and lead carried from its headline and TechCrunch); Colossal Foundation $100M (Wikipedia only); Forbes 2026-03-12 “$615M” figure (403 — conflicts with $555M; not adopted); the Cell Genomics author-list detail rests on a fetched summary, not the PDF.
2026-09-05 — created
- New persona at v2 depth for Moonshots LIVE 2026-09-25 (moonshot interview).
- Verified this pass: the dire wolf method (grey wolf edits, cloning, domestic dog surrogate), the three animals and their names, the “functional de-extinction” definition and IUCN framing, the “stupid argument” quote, the submitted lineage study, $437M raised at $10.2B (Fast Company, 2025-04-12); the flagship-species-as-message framing (Nature careers feature, 2025-09-25 — headline and framing only, full text paywalled).
- Not verified this pass: the 2028 mammoth target is carried from general knowledge and should be confirmed against a Colossal primary source before being used as a scoring date. The George Church co-founding is well established but was not separately sourced here.
- Framed the finding that earns the file: the strongest claim in the corpus is a definition delivered in the grammar of a result — the same move logged against Salim Ismail on the same day, in a different field. Worth watching for as a pattern across this bill.
- Named the failure mode his case adds to the Leapfrog framing: leapfrogging where the outcome is real and the claim about it is inflated. (Originally cited as “§24” — no such principle; corrected 2026-10-03.)
- Confidence medium — the financials and method are documented; the timelines and the spinout case are not.
Sources
- Primary / company: IUCN SSC Canid Specialist Group statement, 2025-04-18 (PDF, read in full) · Gedman et al., “On the ancestry and evolution of the extinct dire wolf,” Cell Genomics, 2026-07-27 (bioRxiv preprint 2025-04) · Colossal on X — Viagen acquisition, 2025-11-04 · Colossal press release, 2025-04-07
- Timelines and money: TIME, 2026-08-24 — mammoth slips to early 2030s · TechCrunch, 2026-07-20 — $20–30B talks, revenue begun · Axios Pro, 2026-09-30 — TWG to lead at $25–26B (headline only) · GenomeWeb, Sep 2025 — $120M, $555M total, $10.32B · Dallas Innovates, 2025-01-15 — Series C $200M, TWG lead · TFN, 2026-08-21 — Astromech $3.8B · D CEO, 2026-03 — Astromech
- Lamm in his own words: Moonshots LIVE 2026-09-25 interview (Scuttlebutt write-up, 2026-10-01) · Fast Company, 2025-04-12 · NPR, 2026-03-04 (not fetched — timed out) · Armchair Expert, Sep 2026 (not listened)
- Critics and disputes: Live Science — Shapiro “grey wolves with 20 edits,” May 2025 · MIT Technology Review, 2026-04-20 — red-wolf clones · New Scientist, 2025-07 — smear campaign · EMBO Reports — “Scientists targeted by dark PR tactics” (paywalled) · Why Evolution Is True, 2025-10-06 — cease-and-desist to Lynch · Scientific American — the debate
- Other: DefenseScoop, 2026-06-17 — UAP Science Advisory Council · CNN, 2026-02-04 — Dubai biovault (451 — headline only) · Gizmodo Science Fair, 2026-09-29 · Wikipedia — Colossal and Ben Lamm (timeline scaffolding only; nothing graded on them alone) · Nature, 2025-09-25 (carried from v1) · Moonshots LIVE 2026
validated + rebuilt on v2.5 CSS 2026-10-03 · backup: _archives/ben-lamm.html.bak-20261003 · converts-from: ben-lamm.html (2026-09-05 v2 build) · Caring + AI & Society domains · Singularity 🧠 / People · open actions: decide the mammoth criterion (drafted above — confirm or edit) · watch the TWG round close and who else is in it · read the 2021–22 launch materials for the retrofit question